Orchid Pharma Limited — Others, 12-08-2025: Change in Auditors

Orchid Pharma's board has approved the financial results for the quarter ended June 30, 2025. Standalone profit was 18.20 Cr, and consolidated profit was 14.91 Cr, with overall net sales at 172.93 Cr. Auditors issued a modified opinion on consolidated results due to unaudited subsidiary financial data. The company has utilized 269.69 Cr of the 391.80 Cr QIP funds, with 124.85 Cr remaining for future use, including a new API facility. Key internal, cost, and secretarial auditor appointments were made. Preparations are also underway for the Annual General Meeting, and the amalgamation petition with Dhanuka Laboratories Limited has been admitted by NCLT.